PeptiSystems Secures Investment to Scale Peptide Manufacturing Amid Growing Demand

UPPSALA, SWEDEN – November 13, 2025 – PeptiSystems AB, a Swedish life science company specializing in advanced manufacturing solutions for peptide and oligonucleotide therapeutics, today announced a significant growth equity investment from Rubicon Healthcare Partners. The funding will be used to accelerate global expansion, scale manufacturing capabilities, and address the increasing demand for these critical therapeutics.

Addressing a Bottleneck in Biopharma Manufacturing

The investment comes at a time of robust growth in the peptide and oligonucleotide therapeutics market, driven by advancements in genetic research and personalized medicine. However, manufacturing capacity remains a key bottleneck. “There’s a growing realization that current manufacturing processes aren't keeping pace with the pipeline of promising new therapies,” stated an industry analyst familiar with the sector. “Companies like PeptiSystems, offering innovative and scalable solutions, are crucial to unlocking the full potential of these therapies.” PeptiSystems’ proprietary “flow-through” column technology aims to address this challenge by offering continuous, automated, and highly efficient production of peptides and oligonucleotides.

Innovative Technology Driving Efficiency and Sustainability

PeptiSystems’ core innovation lies in its departure from traditional batch reactor technology. The “flow-through” system offers significant advantages, including reduced production times, lower solvent consumption, and improved product purity. The system’s ability to seamlessly scale production from research to commercial levels is a key differentiator. “The ability to move from milligram quantities to kilogram scales without significant process changes is a game-changer,” explained a manufacturing expert. “This not only reduces costs but also minimizes the risk of introducing variability during scale-up.” By optimizing synthesis parameters and automating key processes, PeptiSystems is poised to deliver a more sustainable and cost-effective manufacturing model.

Rubicon Healthcare Partners Backs Nordic Growth Story

Rubicon Healthcare Partners’ investment signals a strong vote of confidence in PeptiSystems’ technology and market potential. The firm, focused on Nordic life science companies, recognized the opportunity to support a company poised for rapid growth. “We were attracted to PeptiSystems’ innovative best-in-class instrument portfolio and robust growth strategy,” stated a source close to Rubicon. “The company’s technology addresses a critical need in the market, and we believe it has the potential to become a leading provider of peptide and oligonucleotide manufacturing solutions.” The partnership will provide PeptiSystems with access to valuable expertise and networks to accelerate its expansion into new markets and strengthen its position in existing ones.

Nordic Region as a Hub for Life Science Innovation

The investment in PeptiSystems is part of a broader trend of increasing venture capital activity in the Nordic region. The region has emerged as a hub for life science innovation, driven by strong research universities, a skilled workforce, and a supportive regulatory environment. “The Nordic countries have a unique ecosystem that fosters innovation and entrepreneurship in the life sciences,” explained a venture capital investor. “Companies like PeptiSystems are benefiting from this environment, and we expect to see continued growth in the region.” The region's commitment to sustainability and green technologies is also attracting investment, aligning with the growing demand for environmentally responsible manufacturing practices.

Addressing Supply Chain Vulnerabilities

Beyond expanding capacity, PeptiSystems' technology also addresses critical supply chain vulnerabilities that have plagued the pharmaceutical industry in recent years. By offering a more reliable and scalable manufacturing process, the company can help to mitigate the risk of disruptions and ensure a consistent supply of essential therapies. This is particularly important for peptides and oligonucleotides, which are often used in specialized and life-saving treatments. “Diversifying manufacturing sources and adopting more resilient technologies are essential to building a robust and secure pharmaceutical supply chain,” noted a supply chain expert. “Companies like PeptiSystems are playing a vital role in achieving this goal.”